Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients

Transplantation

Volumn 89, Issue 12, 2010, Pages 1504-1510

  Calmus, Yvon ^a   Kamar, Nassim ^b   Gugenheim, Jean ^c   Duvoux, Christophe ^d   Ducerf, Christian ^e   Wolf, Philippe ^f   Samuel, Didier ^g   Vanlemmens, Claire ^h   Neau Cransac, Martine ⁱ   Salamé, Ephrem ^j   Chazouillères, Olivier ^a   Declerck, Nicole ^k   Pageaux, Georges Philippe ^l   Dubel, Laurence ^m   Rostaing, Lionel ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b CHU RANGUEIL   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g HÔPITAL PAUL BROUSSE   (France)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j CHU CÔTE DE NACRE   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l HÔPITAL SAINT ELOI   (France)

^m Astellas Pharma   (France)

more..

Author keywords

Induction; Liver; Renal function; Tacrolimus; Transplantation

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; CREATININE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; STEROIDS; TACROLIMUS; TIME FACTORS;

EID: 77954083029     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181db8cf0     Document Type: Article

References (21)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
2. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934.
3. Fisher NC, Nightingale PG, Gunson BK, et al. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998; 66: 59.
4. Velidedeoglu E, Bloom RD, Crawford MD, et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. Transplantation 2004; 77: 553.
5. Schmitz V, Laudi S, Moeckel F, et al. Chronic renal dysfunction following liver transplantation. Clin Transplant 2008; 22: 333.
6. Campbell MS, Kotlyar DS, Brensinger CM, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretrans-plantation creatinine elevation. Liver Transpl 2005; 11: 1048.
7. Schlitt HJ, Barkmann A, Boeker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomized controlled study. Lancet 2001; 357: 587.
8. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil mono-therapy in liver transplantation. Lancet 2001; 357: 609.
9. Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755.
10. Reich DJ, Clavien PA, Hodge EE; MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacroli-mus: Randomized, prospective, multicenter pilot study results. Transplantation 2005; 80: 18.
11. Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867.
12. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immu-nosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001; 7: 220.
13. Heffron TG, Smallwood GA, Pillen T, et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transpl Proc 2002; 34: 1514.
14. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064.
15. Sellers MT, McGuire BM, Haustein SV, et al. Two-dose daclizumab induction therapy in 209 liver transplants: A single-center analysis. Transplantation 2004; 78: 1212.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
17. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (campath-1H) and low-dose tacrolimus immuno-suppression in adult liver transplantation. Transplantation 2004; 77: 1209.
18. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxocitiy. Clin Transplant 2008; 22: 1.
19. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327.
20. Boillot O, Mayer D, Boudjema K, et al. Corticoid-free Immunosup-pression with tacrolimus following induction with daclizumab: A large randomized clinical study. Liver Transpl 2005; 11: 61.
21. Bahirwani R, Campbell MS, Siropaides T, et al. Transplantation: Impact of pretransplant renal insufficiency. Liver Transpl 2008; 14: 665.